Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 5/2007

01-09-2007 | Research Article

Age-Related Changes in the Metabolic Activity and Distribution of the Red Marrow as Demonstrated by 2-Deoxy-2-[F-18]fluoro-d-glucose-Positron Emission Tomography

Authors: Chengzhong Fan, Miguel Hernandez-Pampaloni, Mohamed Houseni, Wichana Chamroonrat, Sandip Basu, Rakesh Kumar, Simin Dadparvar, Drew A. Torigian, Abass Alavi

Published in: Molecular Imaging and Biology | Issue 5/2007

Login to get access

Abstract

Objectives

The objective of the study was to determine age-related changes occurring in red marrow with regard to its distribution and the degree of its metabolic activity by whole-body 2-deoxy-2-[F-18]fluoro-d-glucose (FDG)-positron emission tomography (PET).

Methods

This retrospective study included 112 patients (56 male, 56 female, mean age 40 years, range 2–85) who underwent whole-body FDG-PET scans for assessment of disorders that were determined not to affect red marrow activity. These patients were categorized into the following groups with equal gender distribution: 0–15 years (12 individuals), 16–25 years (20), 26–35 years (10), 36–45 years (20), 46–55 years (14), 56–65 years (16), 66–75 years (14), and 76–85 years (6). Whole-body FDG-PET images were performed at 60 min after the intravenous administration of 0.14 mCi/kg of FDG. By employing a dedicated whole-body PET scanner. Maximal standardized uptake value (SUVmax) was calculated from three consecutive transverse sections of the upper thirds of the humeri and femora, manubrium of the sternum, 12th thoracic and 5th lumbar vertebra and anterior superior iliac crests of the pelvis. All available results from other imaging examinations [magnetic resonance imaging (MRI), computed tomography (CT), and conventional radiolography], laboratory data, biopsies, and the clinical course of these subjects were reviewed to make certain that the bone marrow sites examined were free of any known pathologies.

Results

SUVmax in the extremities showed significant decline with aging (correlation coefficient of −0.60 to −0.67, p < 0.01). In contrast, a weak correlation was noted in the axial skeletal activity with advancing age (correlation coefficient of −0.28 to −0.48, p < 0.05).

Conclusions

These data suggest that FDG metabolic activity of the red marrow in the extremities decline significantly with normal aging, while that of the axial skeleton show minimal decrease related to this biologic phenomenon. These findings are of value in assessing the effects of hematological and other disorders in the distribution and the metabolic activity of this important tissue and testing therapeutic interventions that are employed for treating such maladies.
Literature
1.
Zhao P, Liu W, Cui Y (2006) Rapid immune reconstitution and dendritic cell engraftment post-bone marrow transplantation with heterogeneous progenitors and GM-CSF treatment. Exp Hematol 34:951–964, JulPubMedCrossRef
2.
Zhang Y, Adachi Y, Iwasaki M, Minamino K, Suzuki Y, Nakano K, Koike Y, Mukaide H, Shigematsu A, Kiriyama N, Li C, Ikehara S (2006) G-CSF and/or M-CSF accelerate differentiation of bone marrow cells into endothelial progenitor cells in vitro. Oncol Rep 15:1523–1527, JunPubMed
3.
Gazitt Y, Akay C, Thomas C 3rd (2006) No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-Hodgkin’s lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF. Stem Cells Dev 15:269–277, AprPubMedCrossRef
4.
Johnston KL, Farnen JP, Manske BR, Go RS (2005) Abnormal positron emission tomography (PET) scan secondary to the use of hematopoietic growth factors. Haematologica 90(12 Suppl), Dec
5.
Blodgett TM, Ames JT, Torok FS, McCook BM, Meltzer CC (2004) Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin. Clin Nucl Med 29:161–163, MarPubMedCrossRef
6.
Brynes RK, McKenna RW, Sundberg RD (1978) Bone marrow aspiration and trephine biopsy: an approach to a thorough study. Am J Clin Pathol 70:753–759, NovPubMed
7.
Ellis LD, Jensen JN, Westerman MF (1964) Needle biopsy of bone and marrow: an experience with 1,445 biopsies. Arch Intern Med 114:213–214PubMed
8.
James LP, Stass SA, Schumacher HR (1980) Value of imprint preparations of bone marrow biopsies in hematologic diagnosis. Cancer 46:173–177, Jul 1PubMedCrossRef
9.
Jamshidi K, Swaim WR (1971) Bone marrow biopsy with unaltered architecture: a new biopsy device. J Lab Clin Med 77:335–342, FebPubMed
10.
Knowles S, Hoffbrand AV (1980) Bone-marrow aspiration and trephine biopsy (1). Br Med J 281:204–205, Jul 19PubMed
11.
Steiner RM, Mitchell DG, Rao VM, et al. (1993) Magnetic resonance imaging of diffuse bone marrow disease. Radiol Clin North Am 31:383–409PubMed
12.
Federico M, Magin RL, Swartz HM, et al. (1989) Detection of bone marrow involvement in patients with cancer. Tumori 75:90–96PubMed
13.
Alavi A, Kung JW, Zhuang H (2004) Implications of PET based molecular imaging on the current and future practice of medicine. Semin Nucl Med 34:56–69PubMedCrossRef
14.
Belhocine T, Spaepen K, Dusart M, Castaigne C, Muylle K, Bourgeois P, Bourgeois D, Dierickx L, Flamen P (2006) 18FDG-PET in oncology: the best and the worst. Int J Oncol 28:1249–1261, MayPubMed
15.
Kumar R, Nadig MR, Chauhan A (2005) Positron emission tomography: clinical applications in oncology. Part 1. Expert Rev Anticancer Ther (6):1079–1094, Dec 5CrossRef
16.
Wechalekar K, Sharma B, Cook G (2005) PET/CT in oncology—a major advance. Clin Radiol 60:1143–1155, NovPubMedCrossRef
17.
Kazama T, Swanston N, Podoloff DA, Macapinlac HA (2005) Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging 32:1406–1411, Dec. Epub 2005 Aug 31PubMedCrossRef
18.
Meyer MA, Nathan CA (2000) Reduced F-18 fluorodeoxyglucose uptake within marrow after external beam radiation. Clin Nucl Med 25:279–280, AprPubMedCrossRef
19.
Kricun ME (1985) Red-yellow marrow conversion: its effect on the location of some solitary bone lesions. Skeletal Radiol 14:10–19PubMedCrossRef
20.
21.
Dunnhill MS, Anderson JH, Whitehead R (1967) Quantitative histological studies on age changes in bone. J Pathol Bacteriol 94:275–291CrossRef
22.
Vogler JB 3rd, Murphy WA (1988) Bone marrow imaging. Radiology 168:679–693PubMed
23.
Desai AG, Thakur ML (1985) Radiopharmaceuticals for spleen and bone marrow studies. Semin Nucl Med 15:229–238PubMedCrossRef
24.
Datz FL, Taylor A Jr (1985) The clinical use of radionuclide bone marrow imaging. Semin Nucl Med 15:239–259PubMedCrossRef
25.
Engstedt L, Franzen S, Jonsson L, et al. (1958) In vivo localization of colloidal Au198 intravenously injected in polycythemia vera: a preliminary report. Acta Radiol 49:66–71PubMedCrossRef
26.
Silberstein B (1998) Nuclear hematology: the erythron. In: Nucl Med Annual 163–174
27.
Kim C, Reske S.N, Abass Alavi (1996) Bone marrow scintigraphy. In: Henkin R., et al. (eds) Nuclear medicine. By Mosby-Year book, pp 1223–124
28.
Herbert CJ, et al (eds). (1996) Nuclear medicine: diagnosis and therapy. New York, NY: By Thieme medical Publishers, Inc., pp 780–784
29.
Van Dyke D, Price D, Shkurkin C, et al. (1967) Differences in distribution of erythropoietic and reticuloendothelial marrow in hematologic disease. Blood 30:364–374PubMed
30.
Hotze A, Low A, Mahlstedt J, et al. (1984) Combined bone marrow and skeletal scintigraphy in osseous and myelogenous diseases. Rofo 140:717–723PubMed
31.
Blend MJ, Pavel DG (1986) Bone marrow imaging: a comparison study using a 99m Tc-sulphur colloid versus a new 99m Tc microaggregated albumin. Nucl Med Commun 7:787–789PubMedCrossRef
32.
Beamish MR, Brown EB (1974) The metabolism of transferrin-bound 111In and 59Fe in the rat. Blood 43:693–701PubMed
33.
Bourgeois P, Demonceau G, Stegen M, et al. (1991) 99Tcm-HMPAO-labelled leucocytes for bone marrow scintigraphy and evaluation of skeletal lesions: comparison with 99Tcm-HSA colloid results. Nucl Med Commun 12:621–627PubMedCrossRef
34.
Duncker CM, Carrio I, Berna L, et al. (1990) Radioimmune imaging of bone marrow in patients with suspected bone metastases from primary breast cancer. J Nucl Med 31:1450–1455PubMed
35.
Munz DL, Sandrock D, Rilinger N (1990) Comparison of immunoscintigraphy and colloid scintigraphy of bone marrow. Lancet 336:258–259PubMedCrossRef
36.
Reske SN, Buell U (1990) Reduced technetium 99m labelled NCA-95/CEA-antibody uptake in liver due to gentle antibody reconstitution: technical note. Eur J Nucl Med 17:38–41PubMedCrossRef
37.
Reske SN, Karstens JH, Gloeckner W, et al. (1989) Radioimmunoimaging for diagnosis of bone marrow involvement in breast cancer and malignant lymphoma. Lancet 1:299–301PubMedCrossRef
38.
Alavi A, Lakhani P, Mavi A, et al. (2004) PET: a revolution in medical imaging. Radiol Clin North Am 42:983–1001PubMedCrossRef
39.
Cheran SK, Herndon JE 2nd, Patz EF Jr (2004) Comparison of whole-body FDG to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 44:317–325PubMedCrossRef
40.
Durski JM, Srinivas S, Segall G (2000) Comparison of GDF-PET and bone scans for detecting skeletal metastases in patients with non-small cell lung cancer. Clin Positron Imaging 3:97–105PubMedCrossRef
41.
El-Haddad G, Zhuang H, Gupta N, et al. (2004) Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med 34:313–329PubMedCrossRef
42.
Shreve PD, Anzai Y, Wahl RL (1999) Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19:61–77PubMed
Metadata
Title
Age-Related Changes in the Metabolic Activity and Distribution of the Red Marrow as Demonstrated by 2-Deoxy-2-[F-18]fluoro-d-glucose-Positron Emission Tomography
Authors
Chengzhong Fan
Miguel Hernandez-Pampaloni
Mohamed Houseni
Wichana Chamroonrat
Sandip Basu
Rakesh Kumar
Simin Dadparvar
Drew A. Torigian
Abass Alavi
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
Molecular Imaging and Biology / Issue 5/2007
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-007-0100-9

Other articles of this Issue 5/2007

Molecular Imaging and Biology 5/2007 Go to the issue

Research Article

Fusion of Gaussia Luciferase to an Engineered Anti-carcinoembryonic Antigen (CEA) Antibody for In Vivo Optical Imaging

Brief Article

2-Deoxy-2-[F-18]fluoro-d-glucose Accumulation in Ovarian Carcinoma Cell Lines

Research Article

Voxel-based NK1 Receptor Occupancy Measurements with [18F]SPA-RQ and Positron Emission Tomography: A Procedure for Assessing Errors from Image Reconstruction and Physiological Modeling

Research Article

Observer Variation of 2-Deoxy-2-[F-18]fluoro-d-Glucose-Positron Emission Tomography in Mediastinal Staging of Non-Small Cell Lung Cancer as a Function of Experience, and its Potential Clinical Impact

Editorial

First Impact Factor for Molecular Imaging and Biology

Research Article

Comparison of Molecular Markers of Hypoxia and Imaging with 60Cu-ATSM in Cancer of the Uterine Cervix